Skip to main content
. 2012 Dec 28;304(4):L276–L286. doi: 10.1152/ajplung.00299.2012

Fig. 2.

Fig. 2.

Decreased interleukin-6 (IL-6) secretion from Trek-1-deficient MLE-12 (A) and A549 (B) cells after 6 and 24 h of tumor necrosis factor-α (TNF-α) treatment (P < 0.05, n ≥ 3; *compared with untreated cells transfected with a scrambled control peptide; #compared with untreated Trek-1 shRNA-transfected cells; ^TNF-α stimulated control cells compared with TNF-α-stimulated Trek-1-deficient cells). TNF-α receptor-1 (TNFR1) expression was unchanged in Trek-1-deficient cells (C; n = 3). Baseline IL-6 mRNA levels were decreased in Trek-1-deficient A549 cells compared with controls (D; 4.5-fold decrease, P < 0.05, n = 3; we considered a greater than 2-fold change in gene expression as significant). An inhibitor of protein translation, cycloheximide, decreased TNF-α-induced IL-6 release by >95% (*P < 0.05) in both control and Trek-1-deficient cells after 6 h of treatment (E).